on Theranexus (EPA:ALTHX)
THX Pharma Strengthens Financial Position in 2025
THX Pharma, known for its innovative focus on rare neurological diseases, released its 2025 results and cash position for March 2026. The company reported a cash reserve of €22.3 million, bolstered by agreements with Biocodex and Exeltis. These partnerships, alongside a capital increase, provide financial stability for years.
The strategic alliance with Biocodex is a landmark in THX Pharma's growth, involving Batten-1's Phase 3 trial costs. The agreement's total value could reach €173 million, including milestone payments and royalties.
Despite operating income primarily from grants, the company reported losses. The result reflects cost reductions and strategic adjustments in 2025, including a focus on R&D with partners like Diverchim.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Theranexus news